Streetbeat News

Products Services

SIDU

Sidus Space, Inc. (NASDAQ:SIDU) shares dropped 1.1% to $3.570 after announcing the successful launch and deployment of its LizzieSat satellite via SpaceX's Transporter-10 Rideshare mission. The company confirmed receiving signals from LizzieSat in low Earth orbit and plans to launch two more satellites later this year for intelligence solutions in various industries.

Portfolio Pulse from Nabaparna Bhattacharya

March 14, 2024 | 5:09 pm

IOVA

Piper Sandler has reaffirmed its Overweight rating on Iovance Biotherapeutics (NASDAQ:IOVA), increasing its price target from $18.00 to $19.00. The adjustment reflects a potential 28.81% upside from the current share price of $14.75. Iovance Biotherapeutics, a clinical-stage biopharmaceutical company, is focused on developing personalized T-cell therapies for solid tumor cancers and is preparing for potential U.S. regulatory approvals and commercialization.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

JAZZ

HC Wainwright & Co. has maintained its Buy rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowered its price target from $204 to $200. Despite this, shares of Jazz Pharmaceuticals have seen a slight increase of 0.2% in the last 24 hours, trading at $118 per share. A move to the new price target would represent a 69.49% increase from the current share price. Jazz Pharmaceuticals, an Ireland-based biopharmaceutical company, focuses on treatments for sleeping disorders and oncology, with nine approved drugs in its portfolio.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 5:00 pm

IMRX

Immuneering's shares dropped following the announcement of topline results from the Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:52 pm

AAPL

SPY

TSLA

USO

The article discusses the current financial market trends, highlighting hotter Producer Price Index (PPI) data indicating higher inflation at the producer level than expected, and declining retail sales suggesting weakening consumer spending. It mentions the positive early trade money flows in several major tech companies and ETFs, while Tesla and NVIDIA experience negative flows. The International Energy Agency predicts an oil supply deficit throughout 2024, contrary to previous surplus expectations. The article advises investors to consider a more defensive position within the protection band to balance market crosscurrents.

Portfolio Pulse from The Arora Report

March 14, 2024 | 4:47 pm

PBM

Psyence Biomedical shares are trading higher following the Indiana legislature's decision to send a bill to the governor that includes funding for psilocybin clinical research trials.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:46 pm

PG

Recent options trading trends indicate a bearish stance on Procter & Gamble (NYSE:PG) by big-money investors, with a split sentiment of 44% bullish and 55% bearish. The trading activity focuses on a price band between $110.0 and $185.0. The largest trades include both bullish and bearish calls and puts, with significant open interest and volume in specific strike prices. Procter & Gamble, a leading consumer product manufacturer, has a current stock price of $162.3, with neutral RSI indicators and expected earnings release in 36 days. Analysts have mixed opinions, with an average target price of $171.5.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 4:45 pm

NTNX

WIT

Wipro Limited (NYSE:WIT) shares rose after announcing an agreement with Desjardins to modernize consumer banking services using its NetOxygen platform. The deal involves integrating Desjardins' loan origination systems into one platform, aiming to enhance customer experience and efficiency. Additionally, Wipro expanded its partnership with Nutanix, Inc. (NASDAQ:NTNX) to launch a new business unit. Despite these developments, Wipro reported a 1.4% decline in Q4 FY23 gross revenue, with IT services revenue down 2.1% Q/Q.

Portfolio Pulse from Lekha Gupta

March 14, 2024 | 4:41 pm

NVDA

NVIDIA shares are trading lower due to a pullback in the tech sector following the release of February's Producer Price Index (PPI) data. Additionally, a blog post from March 11 comparing NVIDIA's H100 to Intel's Gaudi 2 has been circulating on social media, potentially influencing investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 4:38 pm

IMRX

Immuneering Corporation (NASDAQ:IMRX) announced positive topline results from the Phase 1 trial of IMM-1-104 for treating advanced RAS-mutant solid tumors. The trial showed promising efficacy and safety profiles, with significant lesion regression and no new acquired alterations in RAS or MAPK pathway genes. Immuneering has selected a 320mg dose for the Phase 2a study, with initial Phase 2a data expected in 2024. Despite the positive news, IMRX shares dropped 44.80% to $3.25.

Portfolio Pulse from Vandana Singh

March 14, 2024 | 4:36 pm